International Pediatric Transplant Association (IPTA) 2025
September 18-21, 2025 | Berlin, Germany
The material below is to support scientific exchange. Any content about investigational therapeutics or investigational uses of FDA-approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.
Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.
Renal Function and Isolated Kidney Transplant Outcomes in Primary Hyperoxaluria Type 1 Long-term Lumasiran Treatment
